| (19) |
 |
|
(11) |
EP 4 458 415 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
15.01.2025 Bulletin 2025/03 |
| (43) |
Date of publication A2: |
|
06.11.2024 Bulletin 2024/45 |
| (22) |
Date of filing: 16.08.2018 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
17.08.2017 US 201762546968 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
22165005.4 / 4092020 |
|
18766406.5 / 3668859 |
| (71) |
Applicant: Gilead Sciences, Inc. |
|
Foster City, CA 94404 (US) |
|
| (72) |
Inventor: |
|
- SHI, Bing
Foster City, 94404 (US)
|
| (74) |
Representative: Carpmaels & Ransford LLP |
|
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB) |
|
| |
|
| (54) |
SOLID FORMS OF AN HIV CAPSID INHIBITOR |
(57) The present disclosure relates to pharmaceutically acceptable salts, cocrystals,
and crystalline forms thereof, of a compound which is
N-((
S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((36S,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide,
which is useful in the treatment of a
Retroviridae viral infection including an infection caused by the HIV virus.